Torrent Pharmaceuticals (TPL) was started in 1959 by U N Mehta as Trinity Laboratories. The company changed its name to present one in 1971.
TPL is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
Its manufacturing facilities are located at Indrad (Gujarat) and Baddi (Himachal Pradesh). These units have received various certifications for its quality management such as ISO 9001, ISO 14001 and OHSAS 18001 and ISO/IEC- 17025.
The company’s Indrad plants manufactures bulk drugs, APIs, formulation in form of tablets, capsules and vials. It has annual production capacity of 6000 million kg of formulations and 15000 kg of bulk drugs/APIs.
TPL’s Baddi plant has a manufacturing capacity of 3600 million tablets, 400 million capsules and 18 million oral liquid bottles per annum.
In India the company has 11 sales and marketing divisions. It has 1000 product registrations across 50 countries that includes US Latin America, Russia, Europe, Japan and many more.
TPL's research and development department has a team of 560 scientists engaged in drug discovery, drug development and new drug delivery systems.
The company has subsidiaries namely Zao Torrent Pharma (Russia), Torrent Do Brasil Ltda (Brazil), Torrent Pharma GmbH (Germany), Torrent Pharma Inc. (USA) and Torrent Pharma Philippines Inc. (Philippines).